Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease

被引:84
|
作者
Kumar, Pramod [1 ]
Kaundal, Ravinder K. [1 ]
More, Sandeep [1 ]
Sharma, Shyam S. [1 ]
机构
[1] NIPER, Mol Neuropharmacol Lab, Dept Pharmacol & Toxicol, Mohali 160062, Punjab, India
关键词
Cognition; Parkinson's disease; Dementia; Pioglitazone; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Oxidative stress; Substantia nigra pars compacta; NIGRA PARS COMPACTA; GAMMA AGONIST PIOGLITAZONE; ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT; LESIONED RATS; MOUSE MODEL;
D O I
10.1016/j.bbr.2008.10.010
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The present study was carried out to elucidate the beneficial effect of pioglitazone in cognitive impairment induced by bilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in substantia nigra pars compacta (SNc) in rats, a model of Parkinson's disease. MPTP-lesioned rats showed poor cognitive performance in both passive avoidance task and cued version of the Morris water maze test. This deficit in learning and memory was found to be associated with oxidative stress. Chronic administration of pioglitazone (10 and 30 mg/kg, p.o., starting 5 days prior to MPTP administration and then for next 30 days) in MPTP-lesioned rats improved cognitive performance in passive avoidance task and cued version of the Morris water maze test. Furthermore, pioglitazone treatment also reduced oxidative stress (as evident by reduced malondialdehyde and increased glutathione levels). These results demonstrate the beneficial effects of pioglitazone on cognitive impairment in MPTP induced Parkinson's disease in rats. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 50 条
  • [1] Neurochemical and behavioural effects of acute administration of pioglitazone in the MPTP model of Parkinson's disease
    Barbiero, J.
    Moraes, L.
    Lima, M.
    Andreatini, R.
    Santiago, R.
    Vital, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S256 - S256
  • [2] Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease
    Barbiero, Janaina K.
    Santiago, Ronise M.
    Lima, Marcelo M. S.
    Ariza, Deborah
    Morais, Livia H.
    Andreatini, Roberto
    Vital, Maria A. B. F.
    BEHAVIOURAL BRAIN RESEARCH, 2011, 216 (01) : 186 - 192
  • [3] Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson's disease
    Tang, H.
    Zhu, R.
    Gao, L.
    Nie, K.
    Feng, S.
    Duan, Z.
    Zhang, Y.
    Zhao, X.
    Wang, L.
    Zhao, J.
    Huang, Z.
    MOVEMENT DISORDERS, 2016, 31 : S255 - S255
  • [4] The MPTP model of Parkinson's disease
    Smeyne, RJ
    Jackson-Lewis, V
    MOLECULAR BRAIN RESEARCH, 2005, 134 (01): : 57 - 66
  • [5] Ixeris dentata (Thunb) Nakai attenuates cognitive impairment in MPTP-treated mouse model of Parkinson's disease
    Lee, Sung-Gyu
    Kim, Ki-Whan
    Kang, Hyun
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 (12) : 2911 - 2918
  • [6] Cognitive impairment in Parkinson's disease
    Cosgrove, Jeremy
    Alty, Jane Elizabeth
    Jamieson, Stuart
    POSTGRADUATE MEDICAL JOURNAL, 2015, 91 (1074) : 212 - 220
  • [7] Cognitive impairment in Parkinson's disease
    Majbour, Nour
    El-Agnaf, Omar
    LANCET NEUROLOGY, 2017, 16 (01): : 23 - 24
  • [8] Cognitive impairment in Parkinson's disease
    Pahwa, R
    Paolo, A
    Troster, A
    Koller, W
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (05) : 431 - 441
  • [9] Cognitive impairment in Parkinson's disease
    Kurbanov, B.
    MOVEMENT DISORDERS, 2016, 31 : S65 - S65
  • [10] Cognitive Impairment in Parkinson's Disease
    Montine, Thomas J.
    BRAIN PATHOLOGY, 2010, 20 (03) : 632 - 632